Please use this identifier to cite or link to this item: https://scholarhub.balamand.edu.lb/handle/uob/5994
DC FieldValueLanguage
dc.contributor.authorYuen, Michaelaen_US
dc.contributor.authorCooper, Sandra Ten_US
dc.contributor.authorMarston, Steve Ben_US
dc.contributor.authorNowak, Kristen Jen_US
dc.contributor.authorMcNamara, Elyshiaen_US
dc.contributor.authorMokbel, Nancyen_US
dc.contributor.authorIlkovski, Biljanaen_US
dc.contributor.authorRavenscroft, Gianinaen_US
dc.contributor.authorRendu, Johnen_US
dc.contributor.authorde Winter, Josine Men_US
dc.contributor.authorKlinge, Larsen_US
dc.contributor.authorBeggs, Alan Hen_US
dc.contributor.authorNorth, Kathryn Nen_US
dc.contributor.authorOttenheijm, Coen A Cen_US
dc.contributor.authorClarke, Nigel Fen_US
dc.date.accessioned2022-08-11T08:02:03Z-
dc.date.available2022-08-11T08:02:03Z-
dc.date.issued2015-01-15-
dc.identifier.issn09646906-
dc.identifier.urihttps://scholarhub.balamand.edu.lb/handle/uob/5994-
dc.description.abstractDominant mutations in TPM3, encoding α-tropomyosinslow, cause a congenital myopathy characterized by generalized muscle weakness. Here, we used a multidisciplinary approach to investigate the mechanism of muscle dysfunction in 12 TPM3-myopathy patients. We confirm that slow myofibre hypotrophy is a diagnostic hallmark of TPM3-myopathy, and is commonly accompanied by skewing of fibre-type ratios (either slow or fast fibre predominance). Patient muscle contained normal ratios of the three tropomyosin isoforms and normal fibre-type expression of myosins and troponins. Using 2D-PAGE, we demonstrate that mutant α-tropomyosinslow was expressed, suggesting muscle dysfunction is due to a dominant-negative effect of mutant protein on muscle contraction. Molecular modelling suggested mutant α-tropomyosinslow likely impacts actin-tropomyosin interactions and, indeed, co-sedimentation assays showed reduced binding of mutant α-tropomyosinslow (R168C) to filamentous actin. Single fibre contractility studies of patient myofibres revealed marked slow myofibre specific abnormalities. At saturating [Ca(2+)] (pCa 4.5), patient slow fibres produced only 63% of the contractile force produced in control slow fibres and had reduced acto-myosin cross-bridge cycling kinetics. Importantly, due to reduced Ca(2+)-sensitivity, at sub-saturating [Ca(2+)] (pCa 6, levels typically released during in vivo contraction) patient slow fibres produced only 26% of the force generated by control slow fibres. Thus, weakness in TPM3-myopathy patients can be directly attributed to reduced slow fibre force at physiological [Ca(2+)], and impaired acto-myosin cross-bridge cycling kinetics. Fast myofibres are spared; however, they appear to be unable to compensate for slow fibre dysfunction. Abnormal Ca(2+)-sensitivity in TPM3-myopathy patients suggests Ca(2+)-sensitizing drugs may represent a useful treatment for this condition.en_US
dc.language.isoengen_US
dc.titleMuscle weakness in TPM3-myopathy is due to reduced Ca2+-sensitivity and impaired acto-myosin cross-bridge cycling in slow fibresen_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1093/hmg/ddv334-
dc.identifier.pmid26307083-
dc.identifier.scopus2-s2.0-84949057883-
dc.identifier.urlhttps://api.elsevier.com/content/abstract/scopus_id/84949057883-
dc.contributor.affiliationFaculty of Health Sciencesen_US
dc.description.volume24en_US
dc.description.issue22en_US
dc.description.startpage6278en_US
dc.description.endpage6292en_US
dc.date.catalogued2022-08-11-
dc.description.statusPublisheden_US
dc.identifier.openURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614700/en_US
dc.relation.ispartoftextHuman Molecular Geneticsen_US
Appears in Collections:Department of Medical Laboratory Sciences
Show simple item record

SCOPUSTM   
Citations

35
checked on Apr 20, 2024

Record view(s)

26
checked on Apr 26, 2024

Google ScholarTM

Check

Dimensions Altmetric

Dimensions Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.